Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Where
Wuhan
Age
18 years and over
People
26
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07552467
Phase 1/2Taking people
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shanghai, Taizhou, Wuhan
Age
18 years to 75 years
People
440 worldwide
Run by
Tyligand Pharmaceuticals (Suzhou) Limited
See details and how to joinNCT06385925
Phase 2Taking people
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Where
Jincheng, Jinzhong, Taiyuan
Age
18 years to 80 years
People
40
Run by
Second Hospital of Shanxi Medical University
See details and how to joinNCT06536868
No phaseTaking people
Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
Where
Hangzhou, Shanghai
Age
18 years and over
People
450
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06687408
Phase 1Not yet taking people in China
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Where
Changzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou
Age
18 years and over
People
33
Run by
Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07550842
Phase 2Not yet taking people in China
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
Where
Beijing
Age
18 years to 75 years
People
38
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07551414
Phase 3Enrolling by invitation
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Where
Guangzhou
Age
18 years and over
People
327
Run by
Avistone Biotechnology Co., Ltd.
See details and how to joinNCT06281964
Phase 2Taking people
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
80
Run by
Sun Yat-sen University
See details and how to joinNCT06426511
No phaseTaking people
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Where
Nanchang
Age
18 years to 99 years
People
30
Run by
Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07398599
Phase 2Taking people
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Where
Tianjin
Age
18 years to 75 years
People
25
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07548060
Phase 2Not yet taking people in China
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
Where
Yiwu
Age
18 years and over
People
27
Run by
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07545213
Phase 2Taking people
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
36
Run by
Sun Yat-sen University
See details and how to joinNCT03872661
Phase 2Taking people
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Where
Guangzhou
Age
18 years to 75 years
People
120
Run by
Sun Yat-sen University
See details and how to joinNCT06563999
No phaseTaking people
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Where
Fuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjing
People
100 worldwide
Run by
Shanghai Chest Hospital
See details and how to joinNCT07541521
Phase 1/2Taking people
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Where
Hangzhou, Shanghai
Age
18 years to 75 years
People
324
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT05482568
Phase 3Taking people
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Where
Shanghai
Age
18 years and over
People
720
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06838273
No phaseNot yet taking people in China
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Where
Xi'an
Age
18 years and over
People
28
Run by
Tang-Du Hospital
See details and how to joinNCT07538193
Phase 1Not yet taking people in China
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
Where
Qingdao, Xiamen, Zhengzhou
Age
18 years to 65 years
People
24
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07538973
Phase 2Taking people
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Where
Xiamen
Age
18 years to 75 years
People
49
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06992739
No phaseTaking people
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
Where
Fuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjing
People
200 worldwide
Run by
Shanghai Chest Hospital
See details and how to joinNCT07528066
Phase 2Taking people
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Where
Tianjin
Age
18 years and over
People
20
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07528274
Phase 1Taking people
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Where
Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
Age
18 years and over
People
304 worldwide
Run by
AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00
No phaseTaking people
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Where
Hangzhou, Hefei, Huzhou, Jinan, Nantong, Nanyang, Ningbo, Shanghai, Xuzhou, Yancheng
Age
20 years to 79 years
People
690
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT04937283
No phaseTaking people
Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
Where
Shanghai
Age
18 years and over
People
110
Run by
Shanghai Chest Hospital
See details and how to joinNCT06503744
Phase 3Taking people
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xi’an, Zhengzhou
Age
18 years and over
People
194
Run by
Nuvation Bio Inc.
See details and how to joinNCT06564324